PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
19.28%
Revenue growth 1.25-1.5x MRVL's 15.46%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
21.59%
Gross profit growth above 1.5x MRVL's 12.72%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
34.14%
EBIT growth below 50% of MRVL's 83.91%. Michael Burry would suspect deeper competitive or cost structure issues.
34.14%
Operating income growth under 50% of MRVL's 83.91%. Michael Burry would be concerned about deeper cost or sales issues.
36.43%
Net income growth under 50% of MRVL's 88.60%. Michael Burry would suspect the firm is falling well behind a key competitor.
41.03%
EPS growth under 50% of MRVL's 88.66%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
31.94%
Diluted EPS growth under 50% of MRVL's 88.66%. Michael Burry would worry about an eroding competitive position or excessive dilution.
1.40%
Share count expansion well above MRVL's 0.55%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.52%
Diluted share count expanding well above MRVL's 0.55%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
14.80%
OCF growth under 50% of MRVL's 137.99%. Michael Burry might suspect questionable revenue recognition or rising costs.
9.76%
FCF growth under 50% of MRVL's 105.64%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
631.87%
10Y revenue/share CAGR at 50-75% of MRVL's 1028.90%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
114.89%
5Y revenue/share CAGR under 50% of MRVL's 351.59%. Michael Burry would suspect a significant competitive gap or product weakness.
94.21%
3Y revenue/share CAGR at 75-90% of MRVL's 119.11%. Bill Ackman would expect new product strategies to close the gap.
2203.77%
10Y OCF/share CAGR above 1.5x MRVL's 245.58%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
245.23%
5Y OCF/share CAGR above 1.5x MRVL's 67.17%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
78514.32%
Positive 3Y OCF/share CAGR while MRVL is negative. John Neff might see a big short-term edge in operational efficiency.
1314.76%
Positive 10Y CAGR while MRVL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
501.62%
5Y net income/share CAGR above 1.5x MRVL's 32.15%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
717.34%
Positive short-term CAGR while MRVL is negative. John Neff would see a clear advantage in near-term profit trajectory.
1502.49%
10Y equity/share CAGR 1.25-1.5x MRVL's 1184.87%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
133.59%
5Y equity/share CAGR above 1.5x MRVL's 36.15%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
100.66%
3Y equity/share CAGR above 1.5x MRVL's 26.86%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.65%
AR growth well above MRVL's 2.72%. Michael Burry fears inflated revenue or higher default risk in the near future.
10.80%
Inventory shrinking or stable vs. MRVL's 29.20%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
14.46%
Asset growth above 1.5x MRVL's 2.02%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
8.12%
BV/share growth above 1.5x MRVL's 1.89%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
13.66%
R&D growth drastically higher vs. MRVL's 6.78%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
8.49%
We expand SG&A while MRVL cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.